Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.

, , , , , , , , , , , , , , , ,,
The American Journal of Cardiology
Erasmus MC: University Medical Center Rotterdam

Pietila, K, Hermens, W.T, Harmoinen, A, Baardman, T, Pasternack, A, Topol, E.J, & Simoons, M.L. (1997). Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. The American Journal of Cardiology, 80(8), 1075–1077. doi:10.1016/S0002-9149(97)00606-1